Penicillin Allergy: Delabeling, PEN-FAST Scoring, and the Real Cost of the Label

About 10% of people in the United States report a penicillin allergy, making it the most common drug allergy on medical records. However, when those patients are formally evaluated with skin testing or direct oral amoxicillin challenge, fewer than 5% actually react. Large multicenter studies, including the PALACE randomized trial and the international iNAAN registry, consistently show that more than 90% of self-reported penicillin allergies can be safely removed. Most wrongful labels come from childhood viral rashes mistaken for drug reactions, family history written into a child's chart, or gastrointestinal side effects that were never true immune reactions.

Yes. Even in patients with a confirmed, previously IgE-mediated penicillin allergy, approximately 80% lose their sensitivity within about ten years as penicillin-specific IgE antibodies wane over time. This means that many adults carrying a label based on a real childhood reaction are no longer reactive as adults, even if their original reaction was genuine. This is one of the reasons the 2022 AAAAI Practice Parameter recommends that every labeled patient be formally reassessed rather than assumed to remain allergic. The only exception is a history of severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS, which permanently excludes rechallenge.

PEN-FAST is a validated clinical decision rule published by Trubiano and colleagues in JAMA Internal Medicine in 2020 that risk-stratifies a reported penicillin allergy. It scores four features: a reaction within the past five years, anaphylaxis or angioedema, severe cutaneous adverse reaction, and treatment required for the reaction. A score of zero predicts a less than 1% risk of a true reaction, and scores of two or less carry a negative predictive value around 96% for a positive oral challenge. Low-risk patients can generally proceed directly to an observed oral amoxicillin challenge without formal skin testing, which is what makes the rule so clinically useful.

For most patients, yes. The historical figure of 10% cross-reactivity between penicillins and cephalosporins was based on flawed 1960s studies with penicillin-contaminated early cephalosporins. Modern meta-analyses, including the Picard data, show the actual overall rate is closer to 2%, and cross-reactivity is driven by R1 side chain similarity, not the shared beta-lactam ring. The 2022 AAAAI Practice Parameter states that patients with an unverified, nonanaphylactic penicillin allergy can receive essentially any cephalosporin routinely without prior testing, and cefazolin is particularly safe because it has unique R1 and R2 side chains.

A direct oral amoxicillin challenge is a supervised, in-clinic test in which a low-risk labeled patient is given a therapeutic dose of amoxicillin and observed for about an hour afterward in a setting equipped to manage an allergic reaction. Some protocols use a single full dose, others a graded two-step approach. The clinic stocks epinephrine, antihistamines, oxygen, and intravenous access in case a reaction occurs. In the iNAAN registry of 1,573 patients undergoing this approach, 95.5% were safely delabeled with no episodes of anaphylaxis. A successful challenge is followed immediately by removal of the allergy from the medical record.

Cefazolin is the standard first-line preoperative antibiotic for most orthopedic, abdominal, and cardiovascular surgeries because it covers skin and soft tissue pathogens effectively and has an excellent safety profile. Patients with an unverified penicillin allergy label are often switched to vancomycin or clindamycin, which have worse coverage, higher rates of C. difficile colitis, and, in the Blumenthal BMJ 2018 cohort, a 50% increased risk of surgical site infection. Verifying or removing a penicillin label before elective surgery is one of the clearest opportunities in preventive care, and many surgical programs now actively refer labeled patients for preoperative allergy evaluation.

No. A maculopapular rash appearing during an amoxicillin course is one of the most commonly mislabeled reactions in medicine. When amoxicillin is given during infectious mononucleosis, up to 90% of patients develop a dramatic rash that is not immune-mediated and does not predict future reactions. Any concurrent viral respiratory infection can produce a similar picture. Unless the rash was hives within an hour of a dose, involved breathing difficulty or blistering, or occurred with facial swelling, it is very likely not a true IgE-mediated allergy, and an allergist can confirm this with a direct oral amoxicillin challenge.

Penicillin allergy itself is not inherited in a predictable pattern. There is a modest familial tendency toward atopy and drug reactions in general, but having a parent with a penicillin allergy does not mean a child will be allergic, and a child should not be labeled based only on family history. Unfortunately, this kind of reflexive labeling is common and accounts for a meaningful share of wrongful pediatric allergy records. The 2022 AAAAI Practice Parameter is explicit that family history alone is not a reason to avoid penicillin or to withhold a formal allergy evaluation.

If you experience hives, swelling, wheezing, difficulty breathing, dizziness, or fainting within an hour of a penicillin dose, stop the medication immediately and call emergency services. If you have an epinephrine auto-injector, use it at the first sign of severe symptoms — early epinephrine is the single most important intervention in anaphylaxis. Lie flat with your legs elevated if you feel faint. After any acute reaction, the offending drug should be documented and you should be referred for formal allergist evaluation to clarify the mechanism and plan for future antibiotic needs.